Article ID Journal Published Year Pages File Type
9892232 The Journal of Steroid Biochemistry and Molecular Biology 2005 10 Pages PDF
Abstract
Estrapatch 40 and 60 presents a better benefit/risk ratio compared to Oesclim 50. Thus Estrapach 40 appears to be a good choice for a first-line estrogen replacement therapy with the possibility to increase the dose to Estrapatch 60.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Biochemistry
Preview
Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch® 40 and Estrapatch® 60) with a twice week system
Authors
, , , , ,